Exclusive and partial enteral nutrition for Crohn's disease

Metabolomic Signatures in Pediatric Crohn's Disease Patients with Mild or Quiescent Disease Treated with Partial Enteral Nutrition: A Feasibility Study

Little is known about the metabolic response of pediatric Crohn's disease (CD) patients to partial enteral nutrition (PEN) therapy and the impact of disease activity and inflammation. We analyzed plasma samples from a nonrandomized controlled intervention study investigating the effect of partial enteral nutrition (PEN) on bone health and growth throughout one year with untargeted metabolomics using high-performance liquid chromatography (HPLC) coupled with high-resolution mass spectrometry (HRMS). Thirty-four paired samples from two time points (baseline and 12 months) were analyzed. Patients (median age: 13.9 years, range: 7-18.9 years, 44% females) were in remission or had mild disease activity. The intervention group received a casein-based formula for 12 months, providing ~25% of estimated daily energy requirements. Sparse partial least squares discriminant analysis (splsda) was applied for group discrimination and identifying sources of variation to identify the impact of PEN. We also investigated the correlation of metabolites with inflammation markers, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and fecal calprotectin. After 12 months, our results show substantial difference between PEN and non-PEN groups in the metabolome of CD patients in remission or with mild disease activity. Inflammatory markers were associated with individual compounds and chemical classes such as isoprenoids and phospholipids. Identified compounds comprise metabolites produced by human or bacterial metabolism, as well as xenobiotics recognized as flavoring agents and environmental contaminants and their biotransformation products. Further longitudinal studies that also include patients with higher disease activity are warranted to evaluate the suitability of these metabolic biomarkers for predicting disease activity.

Nomogram to Predict Postoperative Intra-abdominal Septic Complications After Bowel Resection and Primary Anastomosis for Crohn's Disease

BACKGROUND

Postoperative intra-abdominal septic complications of Crohn's disease substantially increase the healthcare expenditure and prolong hospitalization.

OBJECTIVE

We aimed to develop and validate a prediction model for intra-abdominal septic complications after bowel resection and primary anastomosis for Crohn's disease.

DESIGN

This was a retrospective cohort study.

SETTINGS

This study was conducted in a tertiary center.

PATIENTS

Data of 949 Crohn's disease-related primary bowel resections and anastomosis from January 2011 to December 2017 were collected.

MAIN OUTCOME MEASURES

Primary outcomes were prevalence of intra-abdominal septic complications.

RESULTS

Overall prevalence of intra-abdominal septic complications after Crohn's disease surgery was 11.6%. Predictors included preoperative C-reactive protein level ≥40 mg/L (OR = 3.545), preoperative glucocorticoids (OR = 1.829) and infliximab use (OR = 3.365), upper GI involvement (OR = 2.072), and hypoalbuminemia (albumin level <30 g/L, OR = 2.406). Preoperative exclusive enteral nutrition was a protector for postoperative septic complications (OR = 0.192) compared with partial enteral nutrition/parenteral nutrition/straight to surgery. A nomogram was computed to facilitate risk calculation; this had a predictive discrimination, measured as area under the receiver operating characteristic curve, of 0.823.

LIMITATIONS

This model is generated from retrospective data. A major limitation of this model is the lack of external validation.

CONCLUSIONS

A new model to predict postoperative intra-abdominal septic complications was developed, which may guide preoperative optimization and candidate selection for primary anastomosis after bowel resection for Crohn's disease. See Video Abstract at http://links.lww.com/DCR/B178. NOMOGRAMA PARA PREDECIR COMPLICACIONES SéPTICAS INTRAABDOMINALES POSTOPERATORIAS DESPUéS DE RESECCIóN INTESTINAL Y ANASTOMOSIS PRIMARIA EN ENFERMEDAD DE CROHN: Las complicaciones sépticas intraabdominales postoperatorias en la enfermedad de Crohn aumentan sustancialmente los costos de atención médica y prolongan la hospitalización.Nuestro objetivo fue desarrollar y validar un modelo de predicción para las complicaciones sépticas intraabdominales después de resección intestinal y anastomosis primaria en enfermedad de Crohn.Este fue un estudio de cohorte retrospectivo.Este estudio se realizó en un centro de tercer nivel.Se recopilaron datos de 949 resecciones intestinales primarias con anastomosis por enfermedad de Crohn de enero de 2011 a diciembre de 2017.El resultado primario fue la prevalencia de complicaciones sépticas intraabdominales.La prevalencia general de complicaciones sépticas intraabdominales después de cirugía por enfermedad de Crohn fue 11.6%. Los predictores incluyeron un nivel preoperatorio de proteína C reactiva ≥ 40 mg / L (odds ratio = 3.545), glucocorticoides preoperatorios (odds ratio = 1.829) y uso de infliximab (odds ratio = 3.365), compromiso gastrointestinal superior (odds ratio = 2.072) e hipoalbuminemia (albúmina <30g / L, odds ratio = 2.406). La nutrición enteral exclusiva preoperatoria fue un protector para las complicaciones sépticas postoperatorias (odds ratio = 0.192, en comparación con la nutrición enteral parcial / nutrición parenteral / envío directo a cirugía. Se calculó un nomograma para facilitar el cálculo del riesgo; esto tuvo una discriminación predictiva, medida como área bajo la curva de la característica de operación del receptor, de 0.823.Este modelo se generó a partir de datos retrospectivos. Una limitación importante de este modelo es la falta de validación externa.Se desarrolló un nuevo modelo para predecir complicaciones sépticas intraabdominales postoperatorias, que puede guiar la optimización preoperatoria y la selección de candidatos para anastomosis primaria después de resección intestinal en enfermedad de Crohn. Consulte Video Resumen en http://links.lww.com/DCR/B178. (Traducción-Dr. Jorge Silva Velazco).

Targeting NLRP3 Inflammasome in Inflammatory Bowel Disease: Putting out the Fire of Inflammation

Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine, comprised of ulcerative colitis and Crohn's disease. Among the complicated pathogenic factors of IBD, the overaction of inflammatory and immune reaction serves as an important factor. Inflammasome is a form of innate immunity as well as inflammation. Among all kinds of inflammasomes, the NOD-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome is the most studied one, and has been revealed to be involved in the pathogenesis and progression of IBD. Here, in this review, the association between the NLRP3 inflammasome and IBD will be discussed. Furthermore, several NLRP3 inflammasome inhibitors which have been demonstrated to be effective in the alleviation of IBD will be described in this review.

Enteral Nutrition in Adult Crohn's Disease: Toward a Paradigm Shift

Medical and surgical treatments for Crohn's disease are associated with toxic effects. Medical therapy aims for mucosal healing and is achievable with biologics, immunosuppressive therapy, and specialised enteral nutrition, but not with corticosteroids. Sustained remission remains a therapeutic challenge. Enteral nutrition, containing macro- and micro-nutrients, is nutritionally complete, and is provided in powder or liquid form. Enteral nutrition is a low-risk and minimally invasive therapy. It is well-established and recommended as first line induction therapy in paediatric Crohn's disease with remission rates of up to 80%. Other than in Japan, enteral nutrition is not routinely used in the adult population among Western countries, mainly due to unpalatable formulations which lead to poor compliance. This study aims to offer a comprehensive review of available enteral nutrition formulations and the literature supporting the use and mechanisms of action of enteral nutrition in adult Crohn's disease patients, in order to support clinicians in real world decision-making when offering/accepting treatment. The mechanisms of actions of enteral feed, including their impact on the gut microbiome, were explored. Barriers to the use of enteral nutrition, such as compliance and the route of administration, were considered. All available enteral preparations have been comprehensively described as a practical guide for clinical use. Likewise, guidelines are reported and discussed.